George Kirsten C, Kebejian Lisa, Ruth Leigh J, Miller Christopher W T, Himelhoch Seth
a Department of Psychiatry , University of Maryland School of Medicine , Baltimore , Maryland , USA.
J Trauma Dissociation. 2016 Jul-Sep;17(4):494-510. doi: 10.1080/15299732.2016.1141150. Epub 2016 Feb 2.
Although sleep disturbances occur commonly in patients with posttraumatic stress disorder (PTSD) and are associated with adverse outcomes and increased suicidality, they are often inadequately addressed by antidepressant medications.
This review aims to assess whether prazosin reduces nightmares, sleep disturbances, and illness severity in adults with PTSD.
Electronic databases (PubMed, PsycINFO) were searched in September 2014 for randomized controlled trials in adults. Search terms included posttraumatic stress disorder, prazosin, nightmares, and sleep disturbance. Included studies used prazosin and provided objective outcome data related to nightmares and/or sleep quality.
Six studies (191 participants) met the criteria for inclusion. Prazosin was more effective than placebo in improving nightmares (standardized mean difference [SMD] = 1.022, 95% confidence interval [CI] [0.41, 1.62], p = .001), sleep quality (SMD = 0.93, 95% CI [-0.02, 1.88], p = .054; and SMD = 1.14, 95% CI [0.24, 2.03], p = .01), and illness severity (SMD = 1.20, 95% CI [0.79, 1.61], p = .001, with no significant effect on systolic (SMD = -0.01, 95% CI [-0.40, 0.37], p = .94) or diastolic (SMD = 0.30, 95% CI [-0.09, 0.68], p = .154) blood pressure.
PTSD-related nightmares, sleep disturbances, and overall illness severity showed a significant response to treatment with prazosin. With careful dose titration, prazosin was well tolerated and had no significant sustained effect on blood pressure.
尽管睡眠障碍在创伤后应激障碍(PTSD)患者中很常见,且与不良后果及自杀倾向增加相关,但抗抑郁药物往往对其治疗效果不佳。
本综述旨在评估哌唑嗪是否能减轻成人创伤后应激障碍患者的噩梦、睡眠障碍及疾病严重程度。
2014年9月检索电子数据库(PubMed、PsycINFO),查找针对成人的随机对照试验。检索词包括创伤后应激障碍、哌唑嗪、噩梦及睡眠障碍。纳入的研究使用了哌唑嗪,并提供了与噩梦和/或睡眠质量相关的客观结果数据。
六项研究(191名参与者)符合纳入标准。哌唑嗪在改善噩梦(标准化均数差[SMD]=1.022,95%置信区间[CI][0.41, 1.62],p = 0.001)、睡眠质量(SMD = 0.93,95% CI[-0.02, 1.88],p = 0.054;以及SMD = 1.14,95% CI[0.24, 2.03],p = 0.01)和疾病严重程度(SMD = 1.20,95% CI[0.79, 1.61],p = 0.001)方面比安慰剂更有效,对收缩压(SMD = -0.01,95% CI[-0.40, 0.37],p = 0.94)或舒张压(SMD = 0.30,95% CI[-0.09, 0.68],p = 0.154)无显著影响。
与创伤后应激障碍相关的噩梦、睡眠障碍及整体疾病严重程度对哌唑嗪治疗有显著反应。通过仔细的剂量滴定,哌唑嗪耐受性良好,对血压无显著持续影响。